Article Sidebar

PDF
Date Published: 06/06/2026
Abstract Views: 19
Views PDF: 10
DOI: https://doi.org/10.51298/vmj.v561i1.18103
Issue
Vol. 561 No. 1 (2026)
Section
Các bài báo
How to Cite
Ninh , V. K., & Đỗ , V. P. (2026). CLINICAL AND PARACLINICAL CHARACTERISTICS OF PATIENTS WITH PERIHILAR CHOLANGIOCARCINOMA UNDERGOING HEPATECTOMY WITH EXTRAHEPATIC BILE DUCT RESECTION AT VIET DUC UNIVERSITY HOSPITAL. Vietnam Medical Journal, 561(1). https://doi.org/10.51298/vmj.v561i1.18103

CLINICAL AND PARACLINICAL CHARACTERISTICS OF PATIENTS WITH PERIHILAR CHOLANGIOCARCINOMA UNDERGOING HEPATECTOMY WITH EXTRAHEPATIC BILE DUCT RESECTION AT VIET DUC UNIVERSITY HOSPITAL

Việt Khải Ninh 1,, Viết Phú Đỗ 2
1 Vietduc University Hospital
2 Vietnam Military Medical University

Main Article Content

Abstract

Objective: To describe the clinical and paraclinical characteristics of patients with perihilar cholangiocarcinoma. Methods: A retrospective descriptive study was conducted on 36 patients diagnosed with perihilar cholangiocarcinoma who underwent hepatectomy combined with extrahepatic bile duct resection at Viet Duc University Hospital between 2015 and 2025. Results: The mean age was 59,94 ± 9,08 years old, with a female predominance (52,8%). The most common presenting symptoms were jaundice (72,2%), weight loss (33,3%), and right upper quadrant pain (27,8%). Elevated total bilirubin (TB) levels at hospital admission were observed in 80,6% of patients, with a mean concentration of 156,07 ± 122,08 µmol/L, and CA 19-9 was elevated in 88,9% of patients. On CT and/or MRI, type III and IV tumors accounted for 83,4% of cases (Bismuth–Corlette classification). Conclusion: Perihilar cholangiocarcinoma is frequently diagnosed at an advanced stage with the development of progressive obstructive jaundice, most of them belong to type 3, 4 on CT, MRI.

Article Details

Keywords

Klatskin tumor; hilar cholangiocarcinoma; clinical characteristics; paraclinical features.

References

1. Nagino, M., Perihilar cholangiocarcinoma: a surgeon's perspective. Iliver, 2022. 1(1): p. 12-24.
2. Pan, Y., et al., Proposing re-classification of bile duct cancer and intrahepatic cholangiocarcinoma: A suggested modification based on the WHO classification. Eur J Surg Oncol, 2025. 51(10): p. 110386.
3. Sharma, P. and S. Yadav, Demographics, tumor characteristics, treatment, and survival of patients with Klatskin tumors. Ann Gastroenterol, 2018. 31(2): p. 231-236.
4. Lygidakis, N.J., et al., Changing trends in the management of Klatskin tumor. Hepatogastroenterology, 2004. 51(57): p. 689-96.
5. Soares, K.C., et al., Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr, 2014. 3(1): p. 18-34.
6. Jarnagin, W. and C. Winston, Hilar cholangiocarcinoma: diagnosis and staging. HPB (Oxford), 2005. 7(4): p. 244-51.
7. DeOliveira, M.L., et al., Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg, 2007. 245(5): p. 755-62.
8. Liang, B., et al., Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Med Sci Monit, 2015. 21: p. 3555-63.
9. She, W.H., et al., Defining the optimal bilirubin level before hepatectomy for hilar cholangiocarcinoma. BMC Cancer, 2020. 20(1): p. 914.
10. Soares, K.C., et al., Hilar cholangiocarcinoma: diagnosis, treatment options, and management. 2014, 2014. 3(1): p. 18-34.